Skip to main content

Table 4 Estimated haplotype frequency of the two MTHFR SNPs (rs1801133 and rs1801131) and results of haplotype analysis in remission and non-remission groups

From: Influence of genetic polymorphisms in homocysteine and lipid metabolism systems on antidepressant drug response

Group

haplotype

remission (%)

non- remission (%)

OR (95%CI)

χ2

P

P*

Total group

T-A

117 (41)

125 (48)

1

2.795

0.095

 

C-A

127 (44)

79 (30)

1.72 (1.18–2.51)

11.39

0.0007

0.002

C-C

44 (15)

58 (22)

0.81 (0.51–1.29)

4.273

0.039

 

Male subgroup

T-A

40 (41)

60 (48)

1

1.032

0.310

 

C-A

46 (47)

35 (28)

1.97 (1.09–3.57)

8.767

0.003

0.012

C-C

12 (12)

31 (25)

0.58 (0.27–1.26)

5.428

0.020

> 0.05

Femal subgroup

T-A

77 (41)

65 (48)

1

1.703

0.192

 

C-A

81 (43)

44 (32)

1.55 (0.95–2.55)

3.542

0.060

 

C-C

32 (17)

27 (20)

1 (0.54–1.84)

0.485

0.486

 

SSRI subgroup

T-A

59 (39)

74 (45)

1

1.083

0.298

 

C-A

63 (41)

58 (33)

1.46 (0.89–2.41)

2.713

0.100

 

C-C

30 (20)

38 (23)

0.99 (0.55–1.78)

0.470

0.493

 

SNRI subgroup

T-A

58 (43)

51 (53)

1

2.48

0.115

 

C-A

64 (47)

25 (26)

2.25 (1.24–4.09)

10.51

0.001

0.002

C-C

14 (10)

20 (21)

0.62 (0.28–1.34)

4.998

0.025

> 0.05

  1. Abbreviations: SNRI serotonin noradrenaline reuptake inhibitor, OR odds ratio, CI confidence interval
  2. *Adjusted P-value from 1000 permutation tests
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us